10-Q: Yijia Group Reports Q1 2026 Net Loss Amid Revenue Dip

Yijia Group Corp. reported a net loss of $46,301 for the quarter ended July 31, 2025, a slight improvement from the prior year, despite a 4% decrease in total revenue.

Summary

• Net loss for the three months ended July 31, 2025, was $46,301, an improvement from a $55,211 net loss in the same period of 2024.
• Total revenue decreased by 4% to $103,899 for the quarter ended July 31, 2025, from $108,477 in the prior year.
• Gross profit decreased to $68,781 (66% margin) from $73,173 (67% margin) year-over-year.
• Operating expenses decreased by 14.6% to $101,221 from $118,587, primarily due to lower personnel and benefit costs.
• Cash balance increased to $1,046,620 as of July 31, 2025, from $782,810 as of April 30, 2025.
• The company operates in two segments: Consulting Service and Healthcare. For the current quarter, healthcare product sales generated $99,674, and consulting services generated $4,225. In the prior year, all revenue was from healthcare product sales ($108,477).
• A significant portion of cash ($468,926) was uninsured by FDIC as of July 31, 2025.
• Major customers for the current quarter are located in the United States, with Customer A accounting for 43.31% ($45,000) of revenue, Customer B for 34.29% ($35,630), and Customer C for 18.33% ($19,043). In the prior year, one customer in Hong Kong accounted for 100% of revenue.

Sentiment

Score: 4

Explanation: While the net loss decreased and operating cash flow turned positive, revenue declined, and significant internal control weaknesses were identified. The company also has a limited operating history and is in a start-up phase, which inherently carries higher risk. The increase in G&A expenses due to legal and professional fees is also a concern.

Positives

• Net loss decreased by 16.1% to $46,301 from $55,211 year-over-year.
• Total operating expenses decreased by 14.6% ($17,366) due to lower personnel and benefit costs.
• Personnel and benefit costs decreased by 35.3% to $34,928 from $53,984.
• Net cash provided by operating activities was $263,810, a significant improvement from $504,001 used in operating activities in the prior year.
• Cash balance increased by $263,810 during the quarter to $1,046,620.
• Accounts receivable decreased by $252,669, indicating improved collection or lower sales.
• Inventories decreased by $35,118.

Negatives

• Total revenue decreased by 4% to $103,899 from $108,477.
• Gross profit decreased by 6% to $68,781 from $73,173.
• Gross profit margin slightly decreased to 66% from 67%.
• General and administrative expenses increased by 15% to $66,293 from $57,573, primarily due to increased legal and professional fees.
• Income tax expense increased by 41.5% to $13,861 from $9,797.
• The company has a limited operating history and is in a start-up stage with limited revenues since inception.
• Identified material weaknesses in internal controls over financial reporting, including lack of a functioning audit committee and ineffective controls over period-end financial disclosure and reporting processes.
• A significant portion of cash ($468,926 as of July 31, 2025) held by financial institutions was uninsured by FDIC.
• The company has a full valuation allowance on deferred tax assets, indicating uncertainty about their future realization.

Risks

• Limited operating history and start-up stage operations with limited revenues since inception.
• Inherent risks in establishing a new business enterprise, including limited capital resources and possible cost overruns due to price and cost increases in services and products.
• Exposure to significant concentrations of credit risk on cash held in banks, with $468,926 uninsured by FDIC as of July 31, 2025.
• Dependence on a few major customers for revenue (e.g., Customer A, B, and C accounted for 95.93% of revenue in Q1 2026).
• Material weaknesses in internal controls over financial reporting, specifically the lack of a functioning audit committee and ineffective controls over period-end financial disclosure and reporting processes, which could lead to material misstatements in future financial statements.
• Uncertainty regarding the realization of deferred income tax assets, leading to a full valuation allowance.

Future Outlook

The company continues to look for other opportunities which could potentially increase its profits in 2025. Management also stated that the results for the period ended July 31, 2025, are not necessarily indicative of the results to be expected for the entire fiscal year ending April 30, 2026, or for any future period.

Management Comments

• "In the opinion of management, the consolidated financial statements contain all material adjustments, consisting only of normal adjustments considered necessary to present fairly the financial condition, results of operations, and cash flows of the Company for the interim periods presented."
• "Management believes that the material weaknesses set forth above did not have an effect on our financial results. However, management believes that the lack of a functioning audit committee and the lack of a majority of outside directors on our Board of Directors results in ineffective oversight in the establishment and monitoring of required internal controls and procedures, which could result in a material misstatement in our financial statements in future periods."
• "To address these material weaknesses, management has initiated steps to strengthen oversight and financial reporting processes, including implementing more formal procedures for preparing and reviewing period-end financial statements and disclosures. We expect that once these measures are fully implemented and operating for a sufficient period, we will remediate the identified weaknesses."

Industry Context

The filing does not provide specific industry context or trends beyond the company's own operations in consulting and healthcare products. It primarily focuses on internal financial performance.

Corporate Governance

Related Party Transactions

• The company granted 60,000 common stocks to CFO Steve Niu on January 8, 2024, at a fair value of $0.05 per share, subject to one year of service vesting.
• For the three months ended July 31, 2024, net cash provided by financing activities included $52,600 from a related party (a director).

Stakeholder Impact

• Shareholders: Potential for future dilution if capital is raised; risk of material misstatements due to internal control weaknesses; uncertainty regarding future profitability given limited operating history.
• Employees: Personnel and benefit costs decreased, potentially indicating workforce adjustments or reduced compensation for key management.
• Customers: Revenue concentration risk with a few major customers, particularly in the US market for the current quarter.
• Creditors: Improved cash position and positive operating cash flow could be favorable, but limited operating history and internal control weaknesses pose risks.

Next Steps

• Management plans to strengthen oversight and financial reporting processes, including implementing more formal procedures for preparing and reviewing period-end financial statements and disclosures, to remediate identified material weaknesses in internal controls.
• The company continues to look for other opportunities to potentially increase profits in 2025.

Key Dates

Recommendation

While the company showed an improved net loss and positive operating cash flow compared to the prior year, the revenue decline and the identified material weaknesses in internal controls, particularly the lack of a functioning audit committee, present significant governance and operational risks. The company's limited operating history and reliance on a few major customers also add to the uncertainty. A "hold" recommendation is appropriate as the company navigates these challenges and works to remediate its internal control issues, but it is not yet a "buy" due to the inherent risks and early stage of operations.

Keywords

Yijia Group Corp, YJGJ, 10-Q, Quarterly Report, Financial Results, Healthcare Products, Consulting Services, Net Loss, Revenue, Operating Expenses, Cash Flow, Internal Controls, Risk Factors, SEC Filing, Nevada Corporation, Nutripeak Trading Corporation